Quetiapine (Seroquel): Pharmacological Profile
Quetiapine acts primarily through combined dopamine D2 and serotonin 5HT2 antagonism, has a half-life of approximately 6-7 hours, is metabolized predominantly by CYP3A4 (with minimal CYP2D6 involvement), does not interact with P-glycoprotein, and carries a risk of QT prolongation particularly in overdose or with concomitant QT-prolonging medications, though it does not cause persistent QT prolongation at therapeutic doses. 1
Mechanism of Action
Quetiapine's therapeutic efficacy is mediated through antagonism of dopamine D2 receptors (Ki = 626 nM) and serotonin 5HT2A receptors (Ki = 38 nM) 1. The active metabolite norquetiapine demonstrates similar D2 activity but significantly greater 5HT2A activity (Ki = 2.9 nM) compared to the parent compound 1.
Additional receptor binding includes:
- Histamine H1 receptors (Ki = 4.4 nM) - contributing to sedation
- Alpha-1 adrenergic receptors (Ki = 14.6 nM) - contributing to orthostatic hypotension
- Minimal muscarinic M1 activity (Ki = 1086 nM)
- No appreciable benzodiazepine receptor affinity 1
Elimination Half-Life
The mean terminal half-life is approximately 6-7 hours at therapeutic doses 1, 2. Steady-state concentrations are achieved within two days of dosing 1. The pharmacokinetics are dose-proportional within the clinical range, with peak plasma concentrations reached in 1.5-2 hours 1, 2.
CYP2D6 Interactions
Quetiapine is NOT significantly metabolized by CYP2D6 1. In vitro studies demonstrate that CYP3A4 contributes 89% to overall metabolism, while CYP2D6 plays only a minor role 3. Critically, quetiapine does not inhibit CYP2D6 or other major CYP enzymes (1A2, 2C9, 2C19, 3A4) at clinically relevant concentrations 1, 2.
Clinical implication: CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) do not require quetiapine dose adjustment. However, CYP3A4 inducers like phenytoin increase quetiapine clearance, while CYP3A4 inhibitors like ketoconazole decrease clearance, necessitating dose modifications 2, 3.
P-Glycoprotein Interactions
Quetiapine does not interact with P-glycoprotein - there is no evidence in the FDA labeling or research literature indicating P-gp substrate, inhibitor, or inducer properties 1. The drug is eliminated primarily through hepatic CYP3A4-mediated metabolism, with less than 1% excreted unchanged 1.
Effect on QT Interval
At therapeutic doses, quetiapine was not associated with persistent QT prolongation in clinical trials, though a thorough QT study was never conducted 1. However, post-marketing surveillance identified QT prolongation cases in three specific scenarios 1:
- Quetiapine overdose (most common)
- Concomitant QT-prolonging medications
- Patients with electrolyte imbalances or underlying cardiac disease
Recent evidence shows:
- QTc prolongation >60 milliseconds occurred in 13.6% of critically ill patients, with the only significant risk factor being concomitant QT-prolonging medications 4
- No cases of torsades de pointes (TdP) occurred at therapeutic doses without additional risk factors 5
- Among 12 case reports of QT prolongation, all TdP cases involved overdose, drug interactions, or electrolyte abnormalities 5
- Quetiapine is associated with QT prolongation and greater odds of TdP compared to aripiprazole, brexpiprazole, or olanzapine 6
Mechanism: Quetiapine blocks the hERG potassium channel (IKr current), the primary mechanism for drug-induced QT prolongation 7. The degree of hERG inhibition varies among antipsychotics, with quetiapine showing intermediate risk 7.
Effect on Cardiac Conduction
Quetiapine does not significantly affect cardiac conduction (AV node, bundle branches) at therapeutic doses 8, 1. Unlike tricyclic antidepressants which delay AV-node conduction and cause AV block, quetiapine's primary cardiac risk is repolarization abnormalities (QT prolongation) rather than conduction disturbances 8.
Risk Stratification from Guidelines
The European Heart Journal guideline classifies psychotropic medications by arrhythmia risk 8. While the specific classification for quetiapine isn't fully detailed in the provided excerpt, the guideline emphasizes:
- Class B drugs: Possible TdP risk
- Class B drugs*: Known TdP risk, conditional TdP risk, or drugs to avoid in congenital long QT
Clinical approach:
- Baseline ECG before initiating quetiapine in patients with cardiac risk factors
- Avoid combining with other QT-prolonging agents when possible
- Correct electrolyte abnormalities (potassium, magnesium) before and during treatment
- Monitor ECG if dose exceeds typical therapeutic range or in overdose situations